Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aurora Spine Corporation (ASG.V)
Toronto, ON, CA
Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within the Canadian market. The company offers a comprehensive portfolio of products designed to address various spinal conditions, particularly degenerative disc diseases. This includes interspinous process lumbar fusion devices such as the ZIP series (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51). Aurora Spine also provides Ti-Coated polyether ether ketone (PEEK) interbody cages, which are crucial for maintaining space and stability between vertebrae while facilitating bone fusion. Its offerings extend to sterile-packed titanium plasma spray coated spinal fusion implants that promote bone growth. Key interbody products comprise EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar region, and Discovery for cervical applications. The company also manufactures SOLO, an anterior lumbar interbody fusion (ALIF) 3D-printed stand-alone device featuring an integrated plate and spacer system for anatomical preservation and spinal support. For sacroiliac joint issues, Aurora Spine provides SiLo, a posterior fusion device. Furthermore, the DEXA-C cervical interbody system, a porous 3D-printed intervertebral body fusion device with customizable lattice density options, is available to match patient bone quality.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.04% | +2.13% | -12.73% | -9.43% | -12.73% | -11.11% | -21.31% | -22.58% | -66.67% | +17.07% | -82.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+4.6% Q1'26: -1.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+26.4% Q1'26: +42.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+0.9% Q1'26: -0.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-1.8% Q1'26: -3.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-9.3% Q1'26: -18.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.4% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.91× Q1'26: -1.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|
| Revenue |
2.59M
est: 2.61M (-0.9%)
|
14.52M
est: 13.81M (+5.2%)
|
17.56M
est: 30.10M (-41.7%)
|
| EBITDA |
-7.12M
est: -138.9K (-5,028.0%)
|
-446.2K
est: -733.2K (+39.1%)
|
179.9K
est: 6.46M (-97.2%)
|
| EBIT |
-7.51M
est: -305.0K (-2,361.2%)
|
-1.50M
est: -1.61M (+7.1%)
|
-827.5K
est: 4.79M (-117.3%)
|
| Net Income |
-7.51M
|
-1.68M
|
-1.00M
est: 18.14M (-105.5%)
|
| SGA |
8.30M
est: 1.32M (+528.3%)
|
7.54M
est: 6.98M (+8.1%)
|
9.57M
est: 15.76M (-39.3%)
|
| EPS |
-0.35
|
-0.02
|
-0.01
est: 0.23 (-105.5%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chad Clouse | Chief Financial Officer | 227.8K | male |
| Trent J. Northcutt | Founder, President, Chief Executive Officer & Director | 213.3K | male |
| Laszlo Garamszegi | Chief Technology Officer & Founder | 206.5K | male |
| David Meyer | Vice President, Chief Legal Officer & Secretary | 195.6K | male |
| Matt Paxton | Executive Vice President of Sales | — | male |
| Matthew Goldstone | Chief Commercial Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASG.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
